Entry |
|
Name |
Linifanib (USAN/INN) |
Formula |
C21H18FN5O
|
Exact mass |
375.1495
|
Mol weight |
375.3989
|
Structure |
|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
Target |
|
Pathway |
hsa04060 | Cytokine-cytokine receptor interaction |
|
Interaction |
|
Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D09635 Linifanib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D09635 Linifanib (USAN/INN)
VEGFR family
VEGFR1 (FLT1)
D09635 Linifanib (USAN/INN)
VEGFR2 (KDR)
D09635 Linifanib (USAN/INN)
VEGFR3 (FLT4)
D09635 Linifanib (USAN/INN)
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
CSF1R (FMS, CD115)
D09635 Linifanib (USAN/INN)
|
Other DBs |
|
KCF data |
ATOM 28
1 C8x C 13.5100 -21.4200
2 C8y C 13.5100 -22.8200
3 C8x C 14.7224 -23.5200
4 C8x C 15.9349 -22.8200
5 C8y C 15.9349 -21.4200
6 C8x C 14.7224 -20.7200
7 N1b N 17.1660 -20.7090
8 C5a C 18.3712 -21.4047
9 N1b N 19.5535 -20.7219
10 O5a O 18.3716 -22.8196
11 C8y C 20.7475 -21.4112
12 C8y C 20.7476 -22.8197
13 C8x C 21.9601 -23.5196
14 C8x C 23.1725 -22.8195
15 C8y C 23.1723 -21.4109
16 C8x C 21.9598 -20.7111
17 X F 19.5146 -23.5321
18 C1a C 24.3790 -20.7141
19 C8y C 12.2976 -23.5200
20 C8y C 11.1021 -22.8296
21 C8y C 9.8896 -23.5295
22 C8x C 9.8894 -24.9295
23 C8x C 11.0849 -25.6199
24 C8x C 12.2974 -24.9200
25 C8y C 10.8111 -21.4602
26 N5x N 9.4188 -21.3137
27 N4x N 8.8493 -22.5926
28 N1a N 11.7192 -20.4518
BOND 31
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 8 10 2
11 9 11 1
12 11 12 2
13 12 13 1
14 13 14 2
15 14 15 1
16 15 16 2
17 11 16 1
18 12 17 1
19 15 18 1
20 2 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 19 24 1
27 20 25 1
28 25 26 2
29 26 27 1
30 21 27 1
31 25 28 1
|